| Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 MAPK and Akt. | |
| | |
MedLine Citation:
|
PMID: 21426316 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND PURPOSE: Regression of left ventricular hypertrophy by moxonidine, a centrally acting sympatholytic imidazoline compound, results from a sustained reduction of DNA synthesis and transient stimulation of DNA fragmentation. Because apoptosis of cardiomyocytes may lead to contractile dysfunction, we investigated in spontaneously hypertensive rats (SHR), time- and dose-dependent effects of in vivo moxonidine treatment on cardiac structure and function as well as on the inflammatory process and signalling proteins involved in cardiac cell survival/death. EXPERIMENTAL APPROACH: 12 week old SHR received moxonidine at 0, 100 and 400 µg·kg(-1)·h(-1) , s.c., for 1 and 4 weeks. Cardiac function was evaluated by echocardiography; plasma cytokines were measured by elisa and hearts were collected for histological assessment of fibrosis and measurement of cardiac proteins by Western blotting. Direct effects of moxonidine on cardiac cell death and underlying mechanisms were investigated in vitro by flow cytometry and Western blotting. KEY RESULTS: After 4 weeks, the sub-hypotensive dose of moxonidine (100 µg) reduced heart rate and improved global cardiac performance, reduced collagen deposition, regressed left ventricular hypertrophy, inhibited Akt and p38 MAPK phosphorylation, and attenuated circulating and cardiac cytokines. The 400 µg dose resulted in similar effects but of a greater magnitude, associated with blood pressure reduction. In vitro, moxonidine inhibited norepinephrine-induced neonatal cardiomyocyte mortality but increased fibroblast mortality, through I(1)-receptor activation and differential effects on downstream Akt and p38 MAPK. CONCLUSIONS AND IMPLICATIONS: While the antihypertensive action of centrally acting imidazoline compounds is appreciated, new cardiac-selective I(1)-receptor agonists may confer additional benefit. |
| | |
Authors:
|
H Aceros; G Farah; L Cobos-Puc; A M Stabile; N Noiseux; S Mukaddam-Daher |
Related Documents
:
|
21390196 - Global left ventricular performance in non-diabetic non-hypertensive metabolic syndrome... 9350916 - A mutation in the methylenetetrahydrofolate reductase gene is not associated with incre... 21429986 - Igf signaling directs ventricular cardiomyocyte proliferation during embryonic heart de... 2209656 - European multi-centre comparison of thallium 201 and technetium 99m methoxyisobutylison... 6741806 - Factors influencing the one-year mortality of dilated cardiomyopathy. 12019276 - Aldosterone is produced from ventricles in patients with essential hypertension. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: British journal of pharmacology Volume: 164 ISSN: 1476-5381 ISO Abbreviation: Br. J. Pharmacol. Publication Date: 2011 Oct |
Date Detail:
|
Created Date: 2011-09-09 Completed Date: 2012-03-19 Revised Date: 2013-02-08 |
Medline Journal Info:
|
Nlm Unique ID: 7502536 Medline TA: Br J Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 946-57 Citation Subset: IM |
Copyright Information:
|
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society. |
Affiliation:
|
Centre Hospitalier de L'Université de Montréal Research Center, Québec, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antihypertensive Agents / pharmacology* Blood Pressure / drug effects Cell Death / drug effects Cell Survival / drug effects Collagen / metabolism Cytokines / antagonists & inhibitors*, blood, metabolism Echocardiography / methods Fibroblasts / drug effects, metabolism, physiology Fibrosis / drug therapy, metabolism Heart / anatomy & histology, drug effects*, physiology Heart Rate / drug effects Hypertension / drug therapy, physiopathology Hypertrophy, Left Ventricular / drug therapy, metabolism Imidazoles / pharmacology* Inflammation / drug therapy, metabolism Myocardium / enzymology Myocytes, Cardiac / drug effects, metabolism, pathology Phosphorylation / drug effects Proto-Oncogene Proteins c-akt / antagonists & inhibitors*, metabolism Rats Rats, Inbred SHR Rats, Inbred WKY p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors*, metabolism |
| Grant Support | |
ID/Acronym/Agency:
|
MOP-82708//Canadian Institutes of Health Research |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Cytokines; 0/Imidazoles; 75438-57-2/moxonidine; 9007-34-5/Collagen; EC 2.7.11.1/Proto-Oncogene Proteins c-akt; EC 2.7.11.24/p38 Mitogen-Activated Protein Kinases |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Protein kinase A and the exchange protein directly activated by cAMP (Epac) modulate phenotype plast...
Next Document: Preserved arterial vasodilation via endothelial protease-activated receptor-2 in obese type 2 diabet...